Compare UVE & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVE | NTLA |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 925.9M | 986.9M |
| IPO Year | 1992 | 2016 |
| Metric | UVE | NTLA |
|---|---|---|
| Price | $29.65 | $12.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 22 |
| Target Price | ★ $40.00 | $19.83 |
| AVG Volume (30 Days) | 210.9K | ★ 4.2M |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | ★ 70.32 | N/A |
| EPS | ★ 4.23 | N/A |
| Revenue | ★ $1,580,798,000.00 | $57,528,000.00 |
| Revenue This Year | $1.87 | $1.96 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.05 | ★ N/A |
| Revenue Growth | 4.61 | ★ 33.52 |
| 52 Week Low | $18.72 | $5.90 |
| 52 Week High | $35.84 | $28.25 |
| Indicator | UVE | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 37.09 | 70.92 |
| Support Level | $29.11 | $10.13 |
| Resistance Level | $31.25 | $9.62 |
| Average True Range (ATR) | 1.13 | 0.61 |
| MACD | -0.39 | 0.40 |
| Stochastic Oscillator | 8.31 | 93.97 |
Universal Insurance Holdings Inc is a private personal residential homeowner insurance company. The company develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners' lines of business and performs substantially all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The company generates revenue from the collection of premiums, earned net interest and dividend income from the investment portfolio, the collection of reinsurance recoverable and financing fees. The company's primary insurance subsidiaries, (UPCIC) and (APPCIC) provide insurance for personal residential: homeowners, renters/tenants, condo unit owners, and other related coverages.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.